A synthesized peptide derived from human PF4 Released during platelet aggregation. Neutralizes the anticoagulant effect of heparin because it binds more strongly to heparin than to the chondroitin-4-sulfate chains of the carrier molecule. Chemotactic for neutrophils and monocytes. Inhibits endothelial cell proliferation, the short form is a more potent inhibitor than the longer form.
Conjugation:
Unconjugated
Anti-PF4 Monoclonal Antibody . Tested in WB, IHC, IP applications. This antibody reacts with Human, Mouse, Rat.
